Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-07-01

Clinical Trial Update: Oral Enzastaurin in Participants With Relapsed Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial update for oral enzastaurin in relapsed mantle cell lymphoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Enzastaurin (enzastaurin)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Mantle-Cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2020-07-01